about
An overview of cancer/testis antigens expression in classical Hodgkin's lymphoma (cHL) identifies MAGE-A family and MAGE-C1 as the most frequently expressed antigens in a set of Brazilian cHL patients.FOXP3 and CTLA4 overexpression in multiple myeloma bone marrow as a sign of accumulation of CD4(+) T regulatory cells.A microRNA signature profile in EBV+ diffuse large B-cell lymphoma of the elderly.Autologous stem cell transplantation improves quality of life in economically challenged, Brazilian multiple myeloma patients.ATIC-ALK: A novel variant ALK gene fusion in anaplastic large cell lymphoma resulting from the recurrent cryptic chromosomal inversion, inv(2)(p23q35).Cancer/Testis Antigen MAGE-C1/CT7: new target for multiple myeloma therapy.Detection and possible prognostic relevance of p53 gene mutations in diffuse large B-cell lymphoma. An analysis of 51 cases and review of the literature.Angiomirs expression profiling in diffuse large B-Cell lymphoma.Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study.Plasma cell leukemia with t(11;14)(q13;q32) simulating lymphoplasmacytic lymphoma - a diagnostic challenge solved by flow cytometry.The role of regulatory T cells and TH17 cells in multiple myeloma.Number of expressed cancer/testis antigens identifies focal adhesion pathway genes as possible targets for multiple myeloma therapy.Cancer/testis antigens expression and autologous serological response in a set of Brazilian non-Hodgkin's lymphoma patients.Efficacy and safety of bortezomib, thalidomide, and lenalidomide in multiple myeloma: An overview of systematic reviews with meta-analyses.TP53 Regulated Inhibitor of Apoptosis 1 (TRIAP1) stable silencing increases late apoptosis by upregulation of caspase 9 and APAF1 in RPMI8226 multiple myeloma cell line.Activation of the Janus kinase/signal transducer and activator of transcription pathway in multiple myeloma is not related to point mutations in kinase and pseudokinase domains of JAK1.Comparative expression of a set of genes to an internal housekeeping control in CDNA amplified and not amplified by PolyAPCR in non-Hodgkin's lymphoma samples obtained from fine-needle aspiration cytology.Observational study of multiple myeloma in Latin America.Association of VEGFA-2578 C>A polymorphism with clinicopathological aspects and outcome in follicular lymphoma patients.Psychosocial adaptation and quality of life among Brazilian patients with different hematological malignancies.Impact of highly active antiretroviral therapy in the treatment of HIV-infected patients with systemic non-Hodgkin's lymphoma.Can thalidomide be effective to treat plasma cell leptomeningeal infiltration?Response of plasmacytomas to low-dose thalidomide in a patient with refractory multiple myeloma.Bilateral central retinal vein occlusion associated with multiple myeloma.Prognostic significance of vascular endothelial growth factor immunoexpression in the context of adverse standard prognostic factors in multiple myeloma.Serum free light chains and post-transplant lymphoproliferative disorder in patients with renal transplant.TGFbetaR2 aberrant methylation is a potential prognostic marker and therapeutic target in multiple myeloma.Possible influence of clinical stage and type of treatment in the persistence of residual circulating t(14;18)-positive cells in follicular lymphoma patients.Anti-myeloma effects of ruxolitinib combined with bortezomib and lenalidomide: A rationale for JAK/STAT pathway inhibition in myeloma patients.Proteasome and heat shock protein 70 (HSP70) inhibitors as therapeutic alternative in multiple myeloma.Clinical correlations and prognostic relevance of HGF, VEGF AND FGF expression in Brazilian patients with non-Hodgkin lymphoma.MAGE-C1/CT7 and MAGE-C2/CT10 are frequently expressed in multiple myeloma and can be explored in combined immunotherapy for this malignancy.Understanding myeloma cancer stem cells.Analysis of polymorphism at site -174 G/C of interleukin-6 promoter region in multiple myeloma.Epstein-Barr viral load, interleukin-6 and interleukin-10 levels in post-transplant lymphoproliferative disease: a nested case-control study in a renal transplant cohort.Is there any relationship between gene expression of tumor antigens and CD4+ T cells in multiple myeloma?Transcriptome Analysis of Mesenchymal Stem Cells from Multiple Myeloma Patients Reveals Downregulation of Genes Involved in Cell Cycle Progression, Immune Response, and Bone MetabolismPrimary breast lymphoma: an uncommon but curable diseaseComparison of a multiplex reverse transcriptase-polymerase chain reaction for BCR-ABL to fluorescence in situ hybridization, Southern blotting, and conventional cytogenetics in the monitoring of patients with Ph1-positive leukemias.Clinical management of six cases of low-risk primary tonsillar non-Hodgkin's lymphoma
P50
Q34032518-DCE95FCA-C89C-4781-8BD4-6BCD4AF105D0Q34402407-BD531A48-FDBA-40FE-AEE5-592F3DA537B3Q35067988-878E8D0C-B94E-44B9-97B8-1A71BEF8E096Q35473153-8EC513EF-E853-41E9-89B6-571B561682F5Q35809839-8544F010-2DE0-413F-A05E-CF2C124977FEQ35846167-566E6305-A501-42DD-B060-5892A9871766Q35888708-C1AB20DE-2EF6-4477-890B-D5D8B7D8E026Q36782590-A2F7161C-6504-4DE9-B5DE-62C10B17A00CQ36941044-51E4FEA4-165C-417A-8F25-E783E3C57A19Q37683315-CA52D91A-6188-4F44-9790-ABA300CDB4F9Q38001433-5ECA3DAA-F1A0-45B7-9615-CEAE2AAFD464Q38343521-02DFD1BB-EF64-43F2-87E1-165CB127ADE1Q38403243-FD8E20E3-4826-4F23-9517-B752513E935EQ38692632-B42800EB-4931-4437-8302-2EF4161B79A0Q38782155-EAC8F011-4E7D-4701-BA1D-54CF950BA879Q39120515-85CA147B-3D6C-46FB-8890-CD146A822282Q39897267-58B80A46-0F40-4F14-9E8A-1604BAD67052Q40488479-933A169E-55DC-43EE-970F-D1D2707B8AA0Q41085345-BDA4ACD9-A6C1-452C-A4C2-49EB6FB5090FQ43441067-5D354F7C-2C40-4397-A503-6282101AC0BFQ44052958-1AF2DEF3-D7C2-4671-A4E4-D15FB403C351Q44328132-84F398A1-904E-43D2-A58F-A2B24ED4B52CQ44910554-FC5637EB-BF09-407B-9877-FC4C7EA322AAQ44982404-828E1B11-E23C-40FE-96FD-18284EC67C8CQ45085931-824F3C89-07B4-47FC-AFAF-7F3DE30DDF73Q45269184-9A48BBD5-A432-4A9B-A6AB-7B9D35295A1AQ46026571-16A71864-2EE4-445F-8689-82EDFFECF75BQ47435849-C42BF554-4735-4E0B-B79C-0BD78D811E0CQ48744087-AF28E8E7-1401-4FF7-BE23-BB937A8B8D0CQ49569621-A904FE1D-12DB-4BFE-9E06-B3B8A5D4A378Q53221535-39F49F28-3963-436E-94FD-4E00B5D0B514Q54282269-2E2B9FFB-334B-453F-8954-4B9D7609C73EQ54525837-F8676815-6862-4BB2-BBB0-1F3CBF91184CQ54558612-92C5AE7B-8DE0-41AE-9074-10D2A158A574Q54653883-807D7DF8-EC81-4358-A185-B483C14C3A3FQ56897204-454D5EFE-0A55-4752-AD6D-32DB5895927EQ61805666-CD3FA860-587D-4AFA-ADB5-80100C3D8D83Q64048795-54127473-077C-4200-AE13-2B6182C88BE3Q64977461-FECD8F69-541B-490C-80AB-269D2875752BQ73258300-6C8BCB2A-949A-4070-9DD9-48B125BD19A7
P50
description
researcher
@en
name
Gisele W B Colleoni
@en
Gisele W B Colleoni
@nl
type
label
Gisele W B Colleoni
@en
Gisele W B Colleoni
@nl
prefLabel
Gisele W B Colleoni
@en
Gisele W B Colleoni
@nl
P106
P31
P496
0000-0002-7144-4878